Company / EPS (Diluted)
Celldex Therapeutics, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$3.90
FY2025
5-year range
-$3.90 / -$1.64
FY2021-FY2025
Trend
-59.2%
vs FY2024
Sector context
#149 of 159
Health Care
What the data says
Among 159 Health Care companies, Celldex Therapeutics, Inc. is in the bottom 6% for eps (diluted). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-18.99 in FY2018 to $-1.31 in FY2017.
Based on SEC 10-K filings.
-3.90 in FY2025.
Declined from $-2.92 to $-3.90 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 159This company -$3.90 Sector average $2.35
▼
-265.8% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 59.2% year-over-year.
- Ranks #149 out of 159 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2017.
- Lowest eps (diluted) in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.90 | -59.2% |
| FY2024 | -$2.45 | +16.1% |
| FY2023 | -$2.92 | -21.7% |
| FY2022 | -$2.40 | -46.3% |
| FY2021 | -$1.64 | +18.8% |
| FY2020 | -$2.02 | +42.5% |
| FY2019 | -$3.51 | +81.5% |
| FY2018 | -$18.99 | -1349.6% |
| FY2017 | -$1.31 | +93.1% |
| FY2016 | -$18.99 | -1349.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026